KarXT + KarX-EC + KarXT + KarX-EC Arm Matching Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease, Psychosis

Trial Timeline

Jul 31, 2025 → Oct 25, 2027

NCT ID

NCT06947941

About KarXT + KarX-EC + KarXT + KarX-EC Arm Matching Placebo

KarXT + KarX-EC + KarXT + KarX-EC Arm Matching Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Alzheimer Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06947941. Target conditions include Alzheimer Disease, Psychosis.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06947941	Phase 3	Recruiting	Jul 31, 2025	Oct 25, 2027	Alzheimer Disease

Competing Products

20 competing products in Alzheimer Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 2	44
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	40
LY450139 + Placebo	Eli Lilly	Phase 3	77
Solanezumab + Placebo	Eli Lilly	Phase 3	77
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	52
Zagotenemab + Placebo	Eli Lilly	Phase 2	52
Donanemab + Placebo + LY3202626	Eli Lilly	Phase 2	52
Donanemab + Placebo	Eli Lilly	Phase 3	77
GSK4527226	Alector	Phase 2	44
AL002 + Placebo	Alector	Phase 2	44
GSK4527226	Alector	Phase 2	44
AL002	Alector	Phase 2	44
Solanezumab + Placebo	Eli Lilly	Phase 3	77
donanemab	Eli Lilly	Phase 2	52
ATH-1017	LeonaBio	Phase 2/3	57
ATH-1017 + Placebo	LeonaBio	Phase 2/3	57
ATH-1017 + Placebo	LeonaBio	Phase 2	44
NDX-1017 + Placebo	LeonaBio	Phase 1	25
simufilam	Cassava Sciences	Phase 2	44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125	Cassava Sciences	Phase 1	25